Momentum Public Relations
Press Release: July 31, 2019
EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2) (the “Company” or “EXM”), a cultivator and producer of high-grade cannabis extracted ingredients for the pharmaceutical, therapeutic, nutraceutical, and cosmetic industries, is pleased to provide an update on its Portuguese activities.
Significant progress has been achieved in reaching EXM’s technical and scientific objectives as regards its activities in Portugal.
- New R&D facility: Construction of new Research & Development (R&D) facility, located inside the Tec Labs Innovation Centre, the incubator of the Faculty of Sciences of University of Lisbon, Portugal, by EXMceuticals Portugal is complete and the new R&D facility is operational.
- New CBD and terpene research opportunities for various industries: The new R&D facility will enable research into CBD and terpene formulations for the nutraceutical, cosmetics and wellness industries. In the medium term the R&D activities will also target pharmaceutical grade formulations.
- New research project: EXMceuticals Portugal has commenced a new research project under the Portugal 2020 program, which is being executed in the new R&D facility. Portugal 2020 is a Framework Program between Portugal and the European Commission that brings together the five European Structural and Investment Funds.
- Importation, research and development licensing: EXMceuticals Portugal is in the process of obtaining, from INFARMED, the Portuguese National Authority of Medicines and Health Products, research and development authorizations allowing EXM to import cannabis-based ingredients. This will also permit EXM to refine, manufacture and export cannabis-based medicinal products from the pilot-scale refining facility built as part of the new R&D lab. The pilot-scale refinery and manufacturing activities are included in the submitted Portugal 2020 R&D project.
- New R&D analytical procedures: Initial R&D activities regarding CBD extraction, purification and associated analytical procedures have been ongoing for several months, in collaboration with local universities, and have already identified several innovative methods of streamlining and improving the various processes.
- Jobs creation: In the next 12 months, EXM plans to create over 80 highly qualified technical & scientific research jobs in Portugal as we move from our current R&D pilot-scale production towards industrial-scale production and we increase the number and scope of the projects undertaken in our R&D facilities.
Jonathan Summers, Chairman of EXM, added, “Our dedicated R&D activities are now fully functional, and these offer huge scope to create original and unique formulations that will benefit the emerging CBD industry as well as consumers. Our pilot refining and manufacturing capabilities will be fully operational within a few weeks once fully licenced. EXM continues to work very closely with the relevant Portuguese authorities, especially INFARMED, regarding our Portuguese activities. The Portuguese regulators and relevant governmental agencies continue to be very supportive and engaged.”
This is the first step towards creating EXM’s European base for R&D and distribution. The company plans to create an environment for advanced research innovation, training and collaboration with the industry. ”Molecules from cannabis are extraordinary and the scientific community around the world is starting to understand the enormous potential of the plant,” said EXM Chief Innovation Officer Susana Santos. “Our R&D facility includes state of the art equipment and is aimed ensuring the highest standards of quality assurance that will guarantee that our client’s customers are always protected and their expectations fully satisfied.”
ON BEHALF OF THE BOARD OF DIRECTORS OF EXMCEUTICALS INC.
Michel Passebon, Chief Executive Officer and Director
For further information contact:
Investor Relations
Email: investors@exmceuticals.com
Media Enquiries:
Email: media@exmceuticals.com
Europe – Jane Glover: +44 (0) 203 757 4990
North America – Mélanie Guillemette: +1 819 668 2734